Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Laufer

Showing results (101-110 of 189) with videos related to

Pageof 19
Sort By:
Journal of Medicinal Chemistry|December 22, 2006
Design, synthesis, and biological evaluation of phenylamino-substituted 6,11-dihydro-dibenzo[b,e]oxepin-11-ones and dibenzo[a,d]cycloheptan-5-ones: novel p38 MAP kinase inhibitorsStefan A Laufer, Gabriele M Ahrens, Solveigh C Karcher, et al.
Journal of Medicinal Chemistry|April 7, 2007
Synthesis, biological testing, and binding mode prediction of 6,9-diarylpurin-8-ones as p38 MAP kinase inhibitorsDominik R J Hauser, Thomas Scior, David M Domeyer, et al.
Acta Crystallographica. Section E, Structure Reports Online|May 15, 2014
2-(3-{(3R,4R)-4-Methyl-3-[meth-yl(7H-pyrrolo-[2,3-d]pyrimidin-4-yl)amino]-piperidin-1-yl}oxetan-3-yl)aceto-nitrile monohydrateMatthias Gehringer, Ellen Pfaffenrot, Peter R W E F Keck, et al.
European Journal of Medicinal Chemistry|April 1, 2021
Design and synthesis of 1H-pyrazolo[3,4-b]pyridines targeting mitogen-activated protein kinase kinase 4 (MKK4) - A promising target for liver regenerationBent Pfaffenrot, Philip Klövekorn, Michael Juchum, et al.
BMC Complementary and Alternative Medicine|October 5, 2013
Entada africana fraction CH₂Cl₂/MEOH 5% inhibits inducible nitric oxide synthase and pro-inflammatory cytokines gene expression induced by lipopolysaccharide in microgliaBrice Ayissi Owona, Nico Frederic Njayou, Stefan A Laufer, et al.
European Journal of Medicinal Chemistry|November 17, 2020
From off-to on-target: New BRAF-inhibitor-template-derived compounds selectively targeting mitogen activated protein kinase kinase 4 (MKK4)Philip Klövekorn, Bent Pfaffenrot, Michael Juchum, et al.
Journal of Medicinal Chemistry|June 27, 2008
Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front regionStefan A Laufer, Dominik R J Hauser, David M Domeyer, et al.
European Journal of Medicinal Chemistry|July 22, 2022
Scaffold modified Vemurafenib analogues as highly selective mitogen activated protein kinase kinase 4 (MKK4) inhibitorsMichael Juchum, Bent Pfaffenrot, Philip Klövekorn, et al.
Expert Opinion on Therapeutic Patents|July 28, 2023
A patent review of MAPK inhibitors (2018 - present)Valentin R Wydra, Raphael B Ditzinger, Nico J Seidler, et al.
ACS Pharmacology & Translational Science|October 19, 2023
Inherent Fluorescence Demonstrates Immunotropic Properties for Novel Janus Kinase 3 InhibitorsJulian Laux, Mariella Martorelli, Simon Strass, et al.
Pageof 19

Showing results (101-110 of 189) with videos related to

Sort By:
Pageof 19
Journal of Medicinal Chemistry|December 22, 2006
Design, synthesis, and biological evaluation of phenylamino-substituted 6,11-dihydro-dibenzo[b,e]oxepin-11-ones and dibenzo[a,d]cycloheptan-5-ones: novel p38 MAP kinase inhibitorsStefan A Laufer, Gabriele M Ahrens, Solveigh C Karcher, et al.
Journal of Medicinal Chemistry|April 7, 2007
Synthesis, biological testing, and binding mode prediction of 6,9-diarylpurin-8-ones as p38 MAP kinase inhibitorsDominik R J Hauser, Thomas Scior, David M Domeyer, et al.
Acta Crystallographica. Section E, Structure Reports Online|May 15, 2014
2-(3-{(3R,4R)-4-Methyl-3-[meth-yl(7H-pyrrolo-[2,3-d]pyrimidin-4-yl)amino]-piperidin-1-yl}oxetan-3-yl)aceto-nitrile monohydrateMatthias Gehringer, Ellen Pfaffenrot, Peter R W E F Keck, et al.
European Journal of Medicinal Chemistry|April 1, 2021
Design and synthesis of 1H-pyrazolo[3,4-b]pyridines targeting mitogen-activated protein kinase kinase 4 (MKK4) - A promising target for liver regenerationBent Pfaffenrot, Philip Klövekorn, Michael Juchum, et al.
BMC Complementary and Alternative Medicine|October 5, 2013
Entada africana fraction CH₂Cl₂/MEOH 5% inhibits inducible nitric oxide synthase and pro-inflammatory cytokines gene expression induced by lipopolysaccharide in microgliaBrice Ayissi Owona, Nico Frederic Njayou, Stefan A Laufer, et al.
European Journal of Medicinal Chemistry|November 17, 2020
From off-to on-target: New BRAF-inhibitor-template-derived compounds selectively targeting mitogen activated protein kinase kinase 4 (MKK4)Philip Klövekorn, Bent Pfaffenrot, Michael Juchum, et al.
Journal of Medicinal Chemistry|June 27, 2008
Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front regionStefan A Laufer, Dominik R J Hauser, David M Domeyer, et al.
European Journal of Medicinal Chemistry|July 22, 2022
Scaffold modified Vemurafenib analogues as highly selective mitogen activated protein kinase kinase 4 (MKK4) inhibitorsMichael Juchum, Bent Pfaffenrot, Philip Klövekorn, et al.
Expert Opinion on Therapeutic Patents|July 28, 2023
A patent review of MAPK inhibitors (2018 - present)Valentin R Wydra, Raphael B Ditzinger, Nico J Seidler, et al.
ACS Pharmacology & Translational Science|October 19, 2023
Inherent Fluorescence Demonstrates Immunotropic Properties for Novel Janus Kinase 3 InhibitorsJulian Laux, Mariella Martorelli, Simon Strass, et al.
Pageof 19